Agouron
Pharmaceuticals is developing
AG-3340 (
prinomastat), the lead compound in a series of structurally related
metalloproteinase inhibitors, for the potential treatment of
cancer and
age-related macular degeneration.
AG-3340, an oral, non-
peptide inhibitor of
gelatinase types A and B (MMP-2 and -9), MT1-MP (MMP-14) and
collagenase III [234058], was selected following demonstration of activity in a variety of in vivo preclinical models upon oral dosing. In May 1999, phase III trials for lung and
prostate cancers of
AG-3340 in front-line combination with
chemotherapy was begun in the US and Canada [286380,326640]. The tested dose for these trials is 5 to 15 mg bid. Following demonstration of the enhanced efficacy of
chemotherapy when supplemented with
AG-3340 in preclinical
tumor models, pilot combination studies and double-blinded, placebo-controlled phase III trials in 700 patients are in progress for the treatment of
non-small cell lung cancer or advanced
hormone-refractory
prostate cancer [302584,327014]. In August 1999, Agouron initiated a second, confirmatory phase III trial of
AG-3340 in combination with
chemotherapy in patients with advanced
non-small cell lung cancer [337253]. Pharmacokinetic studies have been conducted in healthy male volunteers and single agent dose-escalation studies in patients demonstrated toxicities (grade 1 or 2; joint related) were not doselimiting [302238]. At the 10th European Organization for Research and Treatment of
Cancer (EORTC) meeting in Amsterdam (June 1998), Agouron released encouraging results from two phase I studies and one preclinical study of
AG-3340 [289688]. In a further 15- patient, phase I study of
AG-3340 with
paclitaxel and
carboplatin, the combination was safe and well tolerated [326268].
AG-3340 has demonstrated significant antimetastatic and antitumor activity in animal models, as well as oral bioavailability and a favorable pharmacokinetic profile. Daily doses of 50 mg/kg completely halted growth of Lewis lung
carcinomas in two thirds of test animals and reduced the formation of lung
metastasis (0.5 mm in diameter) by 90% [205708]. In December 1997, Roche announced it would discontinue its
cancer R&D collaborations with Agouron on
AG-3340 as it did not fulfill its scientific and business objectives [271723]. Agouron is investigating analogs of
AG-3340 which are undergoing animal studies [332841].